Mergers and Acquisitions Integration Excellence in Pharma Companies

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

This benchmarking study was conducted to examine winning bio-pharmaceutical M&A integration strategies to provide field benchmarks, lessons learned insights and best practice observations regarding the strategic combination of biotechnology and pharmaceutical assets to optimize ROI.

Executives involved in the merger and acquisition integration process can use this research to ensure their integration strategy reflects the critical lessons learned that participants shared from scores of bio-pharma integrations.

Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Health Care; Manufacturing

Companies Profiled:
3M Pharmaceuticals; Takeda Pharmaceuticals; Solvay Pharmaceuticals; SIRO Clinpharm; QLT Inc.; Pfizer; Nizhpharm; Merial; Medtrina; Lilly; Kimble Chase; Johnson & Johnson Healthcare Systems; Indoco; Incite World; Heel; Eisai; Covidien; Coloplast; Baxter Healthcare; ATG; Alexza Pharmaceuticals; Allergan; Absolute Science; Abbott Laboratories

Study Snapshot

The data for this benchmarking study was collected utilizing an online survey instrument and several deep-dive executive interviews. Bio-pharma integration leaders and senior staff from 26 pharmaceutical and biotechnology companies participated in this research.

Key topics include:

Structure for Integration
Pre-Integration Planning Activities
Integration Risk Management
Integration Functional Excellence
Communications Excellence
Understanding & Managing Cultural Issues
Post-Deal Closure Integration Activities
Trends in M&A Integration
Integration Lessons Learned

Sample Key Findings

Integration structure should reflect the acquired assets & business objectives

Communications excellence is a foundation for succesful integration
Understanding and managing cultural issues is vital to assessing and executing successful integration

Sample List of Charts & Exhibits

Industry Integration Functional Efficacy

Efficacy of Integration Structural Approaches
Integration Planning Initiation
Pre-Integration Planning Activity Efficacy
Integration Planning Activity Resource Intensity
Integration Risk-Assessment Factor Importance
Integration Approach Assessments
Post-Deal Closure Integration Ownership
Time to Integration Stability By Organization Size
Performance Indicators for Integration Performance Measurement
M&A Activity Horizon

M&A Integration Excellence: What Bio-Pharma Companies Need to Know

ID: POP-224

Features:

Pages: 107

Published: Pre-2019

Delivery Format: Shipped

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
627423ECC902326E085257450007210DB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/merger-acquisition-integration-what-bio-pharma-companies-need-to-know
18
19
20172.70.126.232
21
22
23116639.0ncwlf7ax.asia
24/bestp/domrep.nsf
25BMR